These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25261556)

  • 1. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.
    Gordon MS; Robert F; Matei D; Mendelson DS; Goldman JW; Chiorean EG; Strother RM; Seon BK; Figg WD; Peer CJ; Alvarez D; Adams BJ; Theuer CP; Rosen LS
    Clin Cancer Res; 2014 Dec; 20(23):5918-26. PubMed ID: 25261556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
    Rosen LS; Hurwitz HI; Wong MK; Goldman J; Mendelson DS; Figg WD; Spencer S; Adams BJ; Alvarez D; Seon BK; Theuer CP; Leigh BR; Gordon MS
    Clin Cancer Res; 2012 Sep; 18(17):4820-9. PubMed ID: 22767667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
    Choueiri TK; Michaelson MD; Posadas EM; Sonpavde GP; McDermott DF; Nixon AB; Liu Y; Yuan Z; Seon BK; Walsh M; Jivani MA; Adams BJ; Theuer CP
    Oncologist; 2019 Feb; 24(2):202-210. PubMed ID: 30190302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
    Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
    J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.
    Dorff TB; Longmate JA; Pal SK; Stadler WM; Fishman MN; Vaishampayan UN; Rao A; Pinksi JK; Hu JS; Quinn DI; Lara PN
    Cancer; 2017 Dec; 123(23):4566-4573. PubMed ID: 28832978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
    Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
    Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
    Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial.
    Ahluwalia MS; Rogers LR; Chaudhary R; Newton H; Ozair A; Khosla AA; Nixon AB; Adams BJ; Seon BK; Peereboom DM; Theuer CP
    Commun Med (Lond); 2023 Sep; 3(1):120. PubMed ID: 37684373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoglin for targeted cancer treatment.
    Rosen LS; Gordon MS; Robert F; Matei DE
    Curr Oncol Rep; 2014 Feb; 16(2):365. PubMed ID: 24445497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.
    Duffy AG; Ma C; Ulahannan SV; Rahma OE; Makarova-Rusher O; Cao L; Yu Y; Kleiner DE; Trepel J; Lee MJ; Tomita Y; Steinberg SM; Heller T; Turkbey B; Choyke PL; Peer CJ; Figg WD; Wood BJ; Greten TF
    Clin Cancer Res; 2017 Aug; 23(16):4633-4641. PubMed ID: 28465443
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
    Salgia R; Patel P; Bothos J; Yu W; Eppler S; Hegde P; Bai S; Kaur S; Nijem I; Catenacci DV; Peterson A; Ratain MJ; Polite B; Mehnert JM; Moss RA
    Clin Cancer Res; 2014 Mar; 20(6):1666-75. PubMed ID: 24493831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
    Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
    BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.
    Merchan JR; Qin R; Pitot H; Picus J; Liu G; Fitch T; Maples WJ; Flynn PJ; Fruth BF; Erlichman C
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):485-93. PubMed ID: 25556030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.
    Karzai FH; Apolo AB; Cao L; Madan RA; Adelberg DE; Parnes H; McLeod DG; Harold N; Peer C; Yu Y; Tomita Y; Lee MJ; Lee S; Trepel JB; Gulley JL; Figg WD; Dahut WL
    BJU Int; 2015 Oct; 116(4):546-55. PubMed ID: 25407442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
    Patnaik A; LoRusso PM; Messersmith WA; Papadopoulos KP; Gore L; Beeram M; Ramakrishnan V; Kim AH; Beyer JC; Mason Shih L; Darbonne WC; Xin Y; Yu R; Xiang H; Brachmann RK; Weekes CD
    Cancer Chemother Pharmacol; 2014 May; 73(5):951-60. PubMed ID: 24633809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
    Bullock KE; Petros WP; Younis I; Uronis HE; Morse MA; Blobe GC; Zafar SY; Gockerman JP; Lager JJ; Truax R; Meadows KL; Howard LA; O'Neill MM; Broadwater G; Hurwitz HI; Bendell JC
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):465-74. PubMed ID: 21079958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
    Rosen PJ; Sweeney CJ; Park DJ; Beaupre DM; Deng H; Leitch IM; Shubhakar P; Zhu M; Oliner KS; Anderson A; Yee LK
    Clin Cancer Res; 2010 May; 16(9):2677-87. PubMed ID: 20406832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.
    Liu Y; Starr MD; Brady JC; Rushing C; Pang H; Adams B; Alvarez D; Theuer CP; Hurwitz HI; Nixon AB
    Mol Cancer Ther; 2018 Oct; 17(10):2248-2256. PubMed ID: 29997150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
    Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Mekhail T; Bukowski RM; Budd GT; Triozzi P; Borden E; Ivy P; Chen HX; Dolwati A; Dreicer R
    Clin Cancer Res; 2009 Oct; 15(19):6277-83. PubMed ID: 19773375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.